General Information

We are a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. In AAV gene therapy, the viral genes are removed from the AAV, a small, non-pathogenic cold virus, creating a biological delivery vehicle called a vector. A therapeutic gene sequence is then inserted, creating a recombinant vector. Our proprietary AAV gene delivery platform (our NAV Technology Platform) consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors). Our mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing gene therapy products administered directly into the body, or in vivo, based on our NAV Technology Platform.

Employees: 18
Founded: 2008
Contact Information
Address 9712 Medical Center Drive, Suite 100, Rockville, MD 20850, US
Phone Number (240) 552-8181.
Web Address
View Prospectus: REGENXBIO Inc.
Financial Information
Market Cap $557.7mil
Revenues $3.6 mil (last 12 months)
Net Income $-15.8 mil (last 12 months)
IPO Profile
Symbol RGNX
Exchange NASDAQ
Shares (millions): 6.3
Price range $22.00 - $22.00
Est. $ Volume $138.6 mil
Manager / Joint Managers Morgan Stanley/ BofA Merrill Lynch/ Piper Jaffray
CO-Managers Chardan Capital Markets
Expected To Trade: 9/17/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change